DiaSorin S.p.A. (OTCMKTS:DSRLF) Given Consensus Recommendation of “Strong Sell” by Analysts

Shares of DiaSorin S.p.A. (OTCMKTS:DSRLF) have been given an average recommendation of “Strong Sell” by the five research firms that are currently covering the stock, Marketbeat.com reports. Four analysts have rated the stock with a sell recommendation and one has assigned a hold recommendation to the company.

Several brokerages recently commented on DSRLF. BNP Paribas Exane downgraded DiaSorin from a “neutral” rating to an “underperform” rating in a research note on Tuesday, July 7th. UBS Group cut DiaSorin from a “hold” rating to a “sell” rating in a research note on Wednesday, August 12th. Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of DiaSorin in a report on Tuesday, August 4th. Zacks Research lowered DiaSorin from a “hold” rating to a “strong sell” rating in a research report on Thursday, August 6th. Finally, Piper Sandler assumed coverage on DiaSorin in a report on Thursday, June 11th. They set a “neutral” rating on the stock.

DiaSorin Price Performance

Shares of OTCMKTS DSRLF opened at $86.00 on Friday. The company’s fifty day moving average is $80.53 and its 200-day moving average is $76.73. DiaSorin has a twelve month low of $66.50 and a twelve month high of $100.00.

DiaSorin Company Profile

DiaSorin S.p.A. is an Italy?based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company’s shares trade on the Milan Stock Exchange and are available in the United States as over?the?counter (OTC) securities under the symbol DSRLF.

At the core of DiaSorin’s business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples.